<h3>Title</h3>
<h3><span style="font-size: 12.16px;">Non-Macrocyclic Chelators for Metal-based Radiopharmaceuticals</span></h3>
<p><strong><span style="font-size: 12.16px;"><span style="text-decoration: underline;">Abstract</span> :</span></strong></p>
<p style="text-align: justify;">Radiopharmaceuticals are a class of drug that relies on the physical decay of a radionuclide to elicit a diagnostic or therapeutic purpose. While organically derived radiotracers, which employ non-metal radionuclides (e.g., <sup>18</sup>F, <sup>11</sup>C, <sup>123</sup>I), have received considerable attention in the field of nuclear medicine, metal-based radiopharmaceuticals are undoubtedly more versatile and hold great promise for the future. The availability of diverse medicinally useful radiometals with varying physical (half-life, specific activity, emission type) and chemical (hardness, oxidation state, acidity) properties has stimulated research interest in harnessing the potential of radiometals for diagnostic imaging as well as use of the emitted particles “millions of tiny bullets of energy” (α- particles, β - particles and Auger electrons) for therapy to kill welltargeted cancerous cells. Contemporary inorganic radiopharmaceuticals often follow a fourcomponent design and are comprised of a radiometal, bifunctional chelator, linker and targeting vector. This talk will focus on the role of coordination chemistry in the development of chelators for their application in nuclear medicine. The synthesis and detailed studies of three new chelators for hexa- and octa-coordinated (radio)metal ions (e.g., Sc<sup>3+</sup>, Ga<sup>3+</sup>, In<sup>3+</sup>, Lu<sup>3+</sup>) will be discussed</p>